HOLLISTON, Mass., Sept. 29, 2016 /PRNewswire/ -- Biostage,
Inc. (Nasdaq: BSTG), ("Biostage" or the "Company"), a biotechnology
company developing bioengineered organ implants to treat cancers
and other life-threatening conditions of the esophagus, bronchus
and trachea, today announced that it will be presenting at the Cell
& Gene Meeting on the Mesa being held October 5-7, 2016 in La
Jolla, CA. Saverio La Francesca, MD, Executive VP and Chief
Medical Officer of Biostage, will present on Thursday, October 6, 2016 at 3:15 p.m. PT.
Dr. La Francesca will provide a medical and scientific review as
well as outline the Company's expected upcoming near-term
corporate, clinical and regulatory milestones that will enable
Biostage's transition to a clinical-stage company in the coming
months.
Dr. La Francesca will also provide an overview of the Company's
Cellframe™ technology which combines a proprietary
biocompatible scaffold with a patient's own stem cells to create
Cellspan™ organ implants. Biostage is currently
advancing and testing its Cellspan implants in collaborative
pre-clinical studies. The Company is currently conducting
pre-clinical, large-animal safety studies, for its Cellspan
Esophageal Implant product candidate, in compliance with the U.S.
Food and Drug Administration (FDA) Good Laboratory Practice (GLP)
regulations, in support of Biostage's goal of filing an
Investigational New Drug (IND) application with the FDA which the
Company expects to file by year end.
A live video webcast of the Company's presentation will be
available at: www.meetingonthemesa.com/webcast/ and will also be
published on the Alliance for Regenerative Medicine's website
shortly after the event.
About the Cell & Gene Meeting on the Mesa
The Cell
& Gene Meeting on the Mesa is a three-day conference bringing
together senior executives and top decision-makers in the industry
with the scientific community to advance cutting-edge research into
cures. The meeting features a nationally recognized Scientific
Symposium, attended by leading researchers and clinical experts
from around the globe, in conjunction with the industry's premier
annual Partnering Forum, the first event of its kind dedicated
solely to facilitating connections in this sector. Combined, these
meetings attract over 800 attendees, fostering key partnerships
through more than 700 one-on-one meetings while highlighting the
significant clinical and commercial progress in the field.
Please visit www.meetingonthemesa.com/ for full information
including registration. Complimentary attendance at this event is
available for credentialed investors and members of the media only.
Investors should contact Laura
Parsons at lparsons@alliancerm.org and interested media
should contact Lyndsey Scull at
lscull@alliancerm.org.
About Biostage
Biostage is a biotechnology company
developing bioengineered organ implants based on the company's new
Cellframe™ technology which combines a proprietary
biocompatible scaffold with a patient's own stem cells to create
Cellspan™ organ implants. Cellspan implants are being
developed to treat life-threatening conditions of the esophagus,
bronchus or trachea with the hope of dramatically improving the
treatment paradigm for patients. Based on its preclinical data,
Biostage has selected life-threatening conditions of the esophagus
as the initial clinical application of its technology.
Cellspan implants are currently being advanced and tested in
collaborative pre-clinical studies. Pre-clinical, large-animal
safety studies, conducted in compliance with the FDA Good
Laboratory Practice (GLP) regulations, for the Company's Cellspan
Esophageal Implant product candidate have begun, in support of
Biostage's goal of filing an Investigational New Drug (IND)
application with the U.S. FDA in late 2016. The IND will seek
approval to initiate clinical trials for its esophageal implant
product candidate in humans.
For more information, please visit www.biostage.com and connect
with the Company on Twitter and LinkedIn.
Forward-Looking Statements:
Some of the statements in
this press release are "forward-looking" and are made pursuant to
the safe harbor provision of the Private Securities Litigation
Reform Act of 1995. These "forward-looking" statements in this
press release include, but are not limited to, statements relating
to the development expectations and regulatory approval of any of
our products, including those utilizing our Cellframe technology,
by the FDA, EMA, MHRA or otherwise, which expectations or approvals
may not be achieved or obtained on a timely basis or at all; or
success with respect to any collaborations, clinical trials and
other development and commercialization efforts of our products,
including those utilizing our Cellframe technology, which
such success may not be achieved or obtained on a timely basis or
at all. These statements involve risks and uncertainties that may
cause results to differ materially from the statements set forth in
this press release, including, among other things, our ability to
obtain and maintain regulatory approval for our products; plus
other factors described under the heading "Item 1A. Risk Factors"
in our Annual Report on Form 10-K for the fiscal year ended
December 31, 2015 or described in our
other public filings. Our results may also be affected by factors
of which we are not currently aware. The forward-looking statements
in this press release speak only as of the date of this press
release. Biostage expressly disclaims any obligation or undertaking
to release publicly any updates or revisions to such statements to
reflect any change in its expectations with regard thereto or any
changes in the events, conditions or circumstances on which any
such statement is based.
Investor Relations
Contacts:
|
|
Tom
McNaughton
|
Jenene
Thomas
|
Chief Financial
Officer
|
Jenene Thomas
Communications LLC
|
774-233-7321
|
(908)
938-1475
|
tmcnaughton@biostage.com
|
jtc@jenenethomascommunications.com
|
Logo - http://photos.prnewswire.com/prnh/20160330/349802LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biostage-to-present-at-the-cell--gene-meeting-on-the-mesa-300336053.html
SOURCE Biostage, Inc.